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ABSTRACT
Background: To evaluate whether tumour-associated
lymphangiogenesis, that is the formation of new
lymphatic vessels (LVs) induced by a tumour, occurs in
and around conjunctival malignant melanoma (MM).
Methods: Clinical files and conjunctival specimens of 20
patients with histologically diagnosed conjunctival MM
were analysed. Sections were stained with LYVE-1 and
podoplanin antibodies as specific lymphatic endothelial
markers and Ki67 as proliferation marker. The tumour area
and the area covered by LV (LVA), LV number (LVN) and
LV density (LVD) were measured within the tumour and in
the peritumoural area in digital images of the specimen.
The LV results were correlated with the histopathological
characteristics, tumour location, recurrence rate, mito-
mycin C therapy and presence of metastases.
Results: LVs were detected in all specimens within the
tumour and peritumourally. Significantly more Ki67
+
proliferating lymphatic endothelial cells were detected in
the tumour and in the peritumoural tissue up to 300 mm
compared with the surrounding normal conjunctiva
(.300 mm distance). There was a slightly positive
correlation between the tumour size and the LVN and LVA
in the 50 mm zone adjacent to the tumour. We did not
find any significant correlations between LVs and
histopathological and clinical characteristics (location,
shape, relapses, metastases), possibly due to the small
sample sizes. Non-limbal tumours with involvement of
tarsus or fornix showed a tendency towards a higher LVD
compared with limbal tumours.
Conclusion: Conjunctival MMs display tumour-asso-
ciated LV within and around the tumour. The MM seems
to induce lymphangiogenesis not only in the tumour, but
also in its proximity.
Malignant melanomas (MMs) of the conjunctiva
are associated with significant morbidity and
mortality due to high rates of recurrence and
metastasis.
12The dissemination of the tumour is
linked to regional lymph nodes with subsequent
distant metastasis.
3 Compared with cutaneous
MM, conjunctival MM is rare. The annual age-
adjusted incidence rates (per million) vary from
0.15 in Asians to 0.5 in non-Hispanic Caucasians.
45
To date, only a few features have been recog-
nised as prognostic factors for conjunctival MM:
tumour location, expansion, relapse, multifocal
location, involvement of the surgical margins and
tumour depth are known prognostic factors for
metastatic disease.
67 Histopathological character-
istics seem not to be consistently associated with
the clinical outcome.
7
The primary treatment of conjunctival MM is
surgical: complete excision with tumour-cell free
margins represents the therapy of choice but
cannot be sufficiently performed in cases of diffuse
growth. Topical mitomycin C as adjunct therapy
has been established,
8 and cryotherapy, laser
ablation, radiation treatment and chemotherapy
in case of metastasis represent additional treat-
ment options for conjunctival MM.
Conjunctival MMs are rich in blood vessels,
which play a role in systemic haematogenous
metastasis. However, the main route of metastasis
of conjunctival MM is lymphogenic: ultrasonic
examination of the draining lymph nodes or even
surgical removal of the sentinel lymph nodes has
been recommended. Up to now, it was not known
whether conjunctival MMs also display significant
tumour-associated lymphangiogenesis, that is
whether the tumour induces the formation of
new lymphatic vessels.
The extent of lymph node metastasis is sup-
posed to be a major determinant for prognosis and
staging of tumours,
9 and it has been shown that
tumour-induced lymphangiogenesis is a strong risk
factor for tumour metastasis in different human
cancers.
3 9–14 The importance of tumour-induced
lymphangiogenesis for lymphogenic metastasis in
cutaneous MM has been shown recently.
10
The purpose of this study was to determine
whether conjunctival MMs also display tumour-
induced lymphangiogenesis, which may represent
a possible new prognostic factor. We used specific
lymphatic endothelial markers to analyse the
presence of lymphatic vessels (LVs) in the tumour
itself and in the adjacent tissue, and correlated
these data with the clinical outcome and histo-
pathological characteristics of the tumours.
MATERIAL AND METHODS
Patients and conjunctival sections
Clinical files and histological sections of conjuncti-
val MMs of 20 patients who were treated at the
Department of Ophthalmology of the University
Erlangen-Nu ¨rnberg, Germany, between 1987 and
2005, were analysed retrospectively.
The files were screened, and the documented
treatment and follow-up were taken into consid-
eration. The clinical outcome of all patients was re-
evaluated at the end of 2006 and again in 2008 by
interviewing the patients’ general practitioners for
any new progress of the disease since the last visit,
especially for systemic metastasis.
LV staining (LYVE-1 and podoplanin)
For staining of LVs, LYVE-1 served as a specific
marker for lymphatic vascular endothelium. The
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was performed as described previously.
15 Briefly, tissue was fixed
in neutral buffered formalin, embedded in paraffin and cut in
4 mm sections. After deparaffinisation and rehydration, sections
were digested with proteinase K (Dako, Hamburg, Germany)
and incubated for 10 min with horseradish peroxidase (HRP).
Sections of conjunctival MMs were incubated for 30 min with a
rabbit polyclonal antibody against human LYVE-1 (1:100; Dako,
Hamburg, Germany) and HRP-conjugated secondary antibody
before development with 3-amino-9-ethylcarbazole (AEC
+)
substrate (red reaction product) or 3,39-diaminobenzidine
(DAB; brown product). Sections were counterstained with
Mayer haemalaun (Chroma, Mu ¨nster, Germany). Positive
controls were performed on corneoscleral ring specimens and
negative controls with control IgG.
Since LYVE-1 is also expressed on tissue macrophages,
16 17
only clearly identifiable vessels with an erythrocyte-free vessel
lumen were counted as LV, and specimens were double-stained
with podoplanin as a second lymphatic endothelial marker.
For podoplanin immunostaining, polyclonal rabbit antihu-
man antibody against podoplanin (1:200, Dako, Hamburg,
Germany) was used, followed by biotinylated goat antirabbit
IgG for 30 min and detection by a streptavidin peroxidase
complex (using DAB/AEC
+ as the chromogen substrate).
Positive controls were performed as described above.
Ki67 staining
Sections of paraffin embedded specimens were double-stained
with LYVE-1 and monoclonal antibody against Ki67 (clone
MIB-1, Dako, Hamburg, Germany) as a specific marker for
proliferating cells. LVs with at least five endothelial cells with
nuclear Ki67 positivity were considered to be Ki67-positive.
Mitomycin C treatment
The additional topical mitomycin C treatment of conjunctival
MM by eye-drops is standardised in our department as two 14-
day cycles with mitomycin C 0.02% eye-drops five times a day
with a 14-day break. Some patients were not treated with
mitomycin C eye-drops due to allergy or refusal. To analyse the
potential antilymphangiogenic effect of mitomycin C therapy,
tumour specimens of patients who received mitomycin C
treatment and had excisions later on during their clinical course
(because of new suspect lesions) were compared with the
specimens obtained before mitomycin C treatment.
Microscopy and computer-assisted vessel analysis
Histological sections of conjunctival MMs of 20 patients were
taken into consideration. Sections were analysed with a light
microscope (BX51, Olympus Optical Co., Hamburg, Germany),
and digital colour images were taken with a 12-bit CCD camera
(Color-View I, Olympus, Hamburg, Germany; 406 and 1006
magnification). Analyses were performed using Cell ˆF (Olympus,
Hamburg, Germany) and Image J analysing program (available
via http://rsb.info.nih.gov/ij/download.html). Morphometric
LV analysis was performed for the area of the tumour, the
adjacent 50 mm zone, the mid-peripheral zone (50–200 mm), the
peripheral zone (200–300 mm) and the conjunctiva more than
300 mm away from the tumour border (defined as normal
conjunctiva). If the tumour-adjacent area was not completely
represented on the specimen, we evaluated the area as far as
represented. The tumour size was measured as the area covered
by the tumour in the histological section. We determined the
following parameters: (1) the LV number (LVN), (2) the area
covered by LVs (LVA), (3) the LV density (LVD), determined by
measuring the LVN and dividing it by the tumour cross-
sectional area (mm
2).
Functional and statistical analysis
To determine statistical significance, quantitative analyses of
the LVA, LVN and LVD in all analysed areas (intratumoural,
50 mm, 50–200 mm, 200–300 mm and .300 mm peritumoural)
were performed in a standardised procedure using the statistic
program InStat 3 (GraphPad Software, San Diego, California).
Analyses were performed using the non-parametric test for the
Ki67 analysis and the Pearson rank correlation for the
correlation of tumour area to LVN and LVA.
RESULTS
Patients and histopathological characteristics
The median age of the patients in the study was 70.4 years (43–
100 years). Nine women and 11 men were treated. The MM of
13 patients was based on primary acquired melanosis (PAM); in
seven patients, the origin of the MM remained unclear. The
primary treatment was surgical, and 10 patients had an
additional topical mitomycin C treatment. The primary tumour
was located in the fornix (two patients), the tarsus and the
upper lid (five patients) or at the limbus/epibulbar conjunctiva
(seven patients). Six patients showed a widely disseminated
tumour, including some who have had primary excision outside
our department, so that the primary tumour location was not
known. Ten patients showed a diffuse, five a nodular and five a
mixed growing type of the MM. The histopathological
characteristics were: 13 tumours of mixed cell type, five
tumours of spindle cell type and two tumours of epitheloid
cell type.
Eight of the 20 patients showed more than five relapses
during the clinical course. Five patients suffered from metas-
tasis: one patient was diagnosed for gastric metastasis 7 years
after primary diagnosis, two patients for submandibular and
neck spreading after 2 and 3 years, and one patient for
craniopharyngeal metastasis after 1 year, and one patient had
parotical metastasis after 14 years.
Conjunctival MMs display intra- and peritumoural LVs
Using LYVE-1 and podoplanin staining, we identified LVs in all
included MM specimens, both within the tumour itself and in
the adjacent tissue (fig 1). There was a similar staining pattern
for both lymphatic vascular endothelial markers in the
conjunctival MM specimens.
Conjunctival MMs are associated with intra- and peritumoural
lymphangiogenesis
To examine whether conjunctival MMs induce formation of
new LVs, Ki67 staining was performed to detect proliferating
lymphatic endothelial cells in the conjunctival MMs and the
adjacent conjunctival tissue. Immunostaining with Ki67
revealed significantly more proliferating lymphatic endothelial
cells in the tumour and in the directly adjacent conjunctiva
compared with the peripheral zones. Non-parametric tests were
performed for each zone separately with the following results
concerning the ratio of Ki67-positive LVs: (1) tumour versus
tumour adjacent conjunctiva (50 mm zone) p=0.063 (not
significant); (2) tumour versus mid-peripheral zone (50–
200 mm) p=0.021; (3) tumour versus peripheral zone (200–
300 mm) p=0.031; (4) tumour versus distant, presumably
normal conjunctiva .300 mm from the tumour border
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associated active lymphangiogenesis in the tumour and its
proximity.
Influence of tumour cross-sectional area on LVs
We analysed whether the extent of lymphangiogenesis in and
around conjunctival MM was correlated with the tumour area.
Therefore, analyses of the LV parameters LVA, LVN and LVD
were performed in the tumour and in the tumour environment
(50 mm zone, 50–200 mm zone, 200–300 mm zone).
Intratumoural LVN, LVA and LVD were not positively
correlated to the tumour cross-sectional area (results for LVN
and LVA shown as table in fig 3). The LVN and LVA in the
50 mm area directly adjacent to the tumour are positively
correlated to the tumour cross-sectional area; the results for the
LVN are demonstrated as a scatter plot in fig 3 (Pearson
correlation coefficient r=0.64; p=0.002). There was a slightly
inverse correlation for the LVD in the tumour with the tumour
cross-sectional area (r=20.257, p=0.237).
Effect of mitomycin C therapy on LVs
We analysed the potential effect of topical mitomycin C
treatment on LV formation.
Specimens of patients (n=4) who underwent topical
mitomycin C treatment after tumour excision and had
subsequent excisions for tumour recurrence were analysed for
LVD and LVN (fig 4). In three patients, the specimens
represented all five zones; in one patient, the specimens showed
only a tumour without surrounding conjunctiva because of
diffuse tumour growth (therefore only the tumour zone was
analysed in this patient). Because of the limited number of
patients, the statistical analysis was restricted to descriptive
analyses (fig 4). An additional LV analysis (LVD, LVN, LVA) of
specimens from mitomycin C treated patients compared with
specimens from patients without mitomycin C treatment did
not show any statistically significant results.
Analysis of LVs in relation to tumour location
Analysing the location of the tumour, seven patients had
limbal/epibulbar tumours, seven patients had a MM at the
fornix or tarsus, and six patients had a disseminated MM. The
analyses of LV parameters (LVN, LVA, LVD) did not show
statistically significant results in these small sample sizes.
Because of the small number of patients, we performed only
descriptive analyses as a scatter plot. Figure 5 demonstrates the
LVD in relation to the tumour location. In four of seven
patients with non-limbal MMs with involvement of the fornix
or tarsus, the LVD was higher than in all limbal tumour
specimens (n=7).
DISCUSSION
This study on conjunctival MM shows for the first time that
conjunctival—and not only cutaneous—MMs display tumour-
associated lymphangiogenesis.
In our study, we found LVs in the tumour itself as well as in
the peritumoural area. These erythrocyte-free LVs are stained
with two new markers specific for lymphatic vascular endothe-
lium, which are LYVE-1 and podoplanin. Most remarkably, the
Figure 1 Tumour-associated lymphatic
vessels (LVs) in malignant melanomas
(MMs) of the conjunctiva. (A)
Representative image of LV staining with
LYVE-1 antibody as specific marker for
lymphatic endothelium: LYVE-1 positive
peritumoural LVs. (B) Representative
image of podoplanin stained LVs in the
tumour adjacent conjunctiva. (C)
Intratumoural LYVE-1 positive LVs
(magnification 6100/6200). The area of
primary acquired melanosis is marked
with an asterisk. Arrows denote the
LYVE-1/podoplanin stained lymphatic
vessels. Note that erythrocyte-filled blood
vessels are not stained with these
lymphatic endothelial specific markers.
LU, lymphatic vessel lumen.
Clinical science
Br J Ophthalmol 2009;93:1529–1534. doi:10.1136/bjo.2008.147355 1531degree of actively proliferating Ki67 positive lymphatic vascular
endothelial cells is significantly higher within the MM and in
the close vicinity of the tumour compared with normal, resting
conjunctival LVs more distant from the tumour site. The ratio
of Ki67 positive LVs is reduced with growing distance from the
tumour border, which supports the hypothesis of active
tumour-induced formation of new LVs (tumour-associated
lymphangiogenesis). It has been shown recently that lymphan-
giogenic growth factors, which are secreted by a primary
tumour, can induce lymphangiogenesis.
20–23
In our small pilot study, there was no significant
correlation between tumour size (two-dimensional) and
LVN and LVA in the tumour. The analyses of the tumour
environment revealed a higher LVN and LVA in the 50 mm
zone directly adjacent to the tumour, possibly being an
indicator for active lymphangiogenesis in the tumour
surroundings. We found a slightly inverse correlation
between LVD in the tumour and the tumour cross-sectional
area. On the one hand, this finding might be related to the
two-dimensional calculations of the tumour area based on
cross-sectional specimens of the tumour. On the other hand,
small tumours might show a higher LVD as a signal for their
starting potency of dissemination, possibly related to high
secretion rates of lymphangiogenic growth factors. Another
possible aspect is a centrally developing necrosis in larger
tumours which might reduce the rate of lymphangiogenesis
and cause reduced LVD. Furthermore, some studies describe a
high interstitial pressure within tumours that promotes LV
collapse;
13 thus, compressed LVs in larger tumours might
appear smaller than LVs in smaller tumours.
We analysed the putative impact of lymphangiogenesis on
recurrence rate and metastasis but did not find any significant
correlation, possibly related to the small sample sizes. Larger
(prospective) studies now will have to evaluate tumour-
associated lymphangiogenesis as a putative risk factor for
tumour metastasis.
Tumour location is one of the clinically most important
prognostic predictors of conjunctival MM: non-limbal tumours
show a higher incidence of initial systemic metastasis and
reduced survival rates.
57This fact might be due to facilitated
access to blood vessels or to the draining LVs Our descriptive
analysis of the tumour location, that is limbal versus palpebral/
fornix versus disseminated conjunctival in correlation with
parameters of lymphangiogenesis, showed a tendency of higher
LVD in non-limbal palpebral/fornix tumours. We did not find
any significant differences concerning the lymphangiogenic
parameters in correlation with the different growth patterns,
that is the shape of the conjunctival MM. Additional studies are
necessary to elucidate these aspects.
Topical mitomycin C treatment might provide an antilym-
phangiogenic effect, as has been suggested in several other
studies on the treatment of conjunctival MM.
81 8We performed
only descriptive analyses due to the small sample sizes of
histological tumour specimens after mitomycin C treatment:
there was a tendency of reduced LVD in specimens from
patients after mitomycin C therapy compared with specimens
before mitomycin C therapy, while LVN and LVA were not
reduced. Nevertheless, other factors such as fibrotic tissue-
remodelling after surgical excision, the influence of co-medica-
tions as topical steroids or other causes cannot be ruled out and
may have a significant influence.
The prognostic importance of intra- and peritumoural
lymphangiogenesis is becoming more established by a growing
number of studies on several human cancers.
391 0The identifica-
tion of high-risk patients is helpful in order to individually
optimise screening and treatment guidelines. The extent of
tumour-associated lymphangiogenesis in conjunctival MM may
be one novel prognostic criterion besides other known or
putative risk factors. Immunostaining for lymphatic markers
such as LYVE-1 and podoplanin in routine histological work-up
of tumour samples might be warranted if future studies reveal a
correlation between tumour-induced lymphangiogenesis and
prognosis of the tumour in terms of metastasis and recurrence
rate. The histological analysis of lymphangiogenesis parameters
compared with sentinel lymph node biopsy as a mean of guiding
treatment and follow-up is under discussion.
91 21 9
This study on tumour-associated lymphangiogenesis may
pave the road to new targets for innovative therapeutic
approaches and serve as a novel prognostic parameter in
Figure 2 Tumour-induced lymphangiogenesis. Significantly more
proliferating lymphatic vessels (LVs) were found intratumourally and next
to the tumour than in distant conjunctiva (.300 mm). Representative
images of conjunctival malignant melanoma specimen stained with
LYVE-1 and proliferation marker Ki67. Ki67 positive cells are marked
(arrowhead). (A) Representative image of Ki67 positivity in tumour-
associated lymphatic endothelial cells; red: Ki-67; brown: LYVE-1
(magnification 61000). (B) Significantly more proliferating LVs were
found intratumourally as well as in the directly adjacent tumour
environment than in the more distant conjunctiva. A paired t test was
performed for each zone separately with the following results: (1) tumour
versus tumour adjacent conjunctiva (50 mm zone) p=0.063 (not
significant); (2) tumour versus mid-peripheral zone (50–200 mm)
p=0.021; (3) tumour versus peripheral zone (200–300 mm) p=0.031;
(4) tumour versus conjunctiva .300 mm from the tumour border
p=0.002; n=20, median is marked; circles mark three outliers. The
results support the hypothesis of tumour-associated active
lymphangiogenesis in the proximity of the tumour.
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antiangiogenic research has been made to develop new
therapeutic approaches to inhibit tumour spreading. Recently,
different assays of selective inhibition of LV growth on the
ocular surface have been shown.
24 25 In the future, antilym-
phangiogenic treatment options might help to minimise the risk
of metastasis in conjunctival MM.
CONCLUSION
MMs of the conjunctiva display LVs within and around the
tumour. There is evidence for tumour-induced lymphangiogen-
esis, that is formation of newly formed LVs. These LVs may act as
conduits for tumour metastasis. Lymphangiogenesis parameters
such as LVD and LVN may become useful novel prognostic
indicators for conjunctival MM. Novel antilymphangiogenic
Figure 3 Influence of tumour cross-
sectional area on lymphatic vessels (LVs).
Analyses of the LV parameters area
covered by LV (LVA), LV number (LVN)
and LV density (LVD) were performed in
the tumour and in the tumour environment
(50 mm zone, 50–200 mm zone, 200–
300 mm zone). Intratumoural LVN, LVA
and LVD were not positively correlated to
the tumour cross-sectional area (A).
There was a slightly inverse correlation
for the LVD in the tumour with the tumour
cross-sectional area (r=20.257,
p=0.237). The LVN in the 50 mm area
directly adjacent to the tumour was
positively correlated to the tumour cross-
sectional area (Pearson correlation
coefficient r=0.64; p=0.002),
demonstrated as a scatter plot (B).
Figure 4 Effect of topical mitomycin C on lymphatic vessels (LVs):
scatter plot of the measured LV density (LVD) in the tumour (0), in the
adjacent 50 mm zone (50), in the 50–200 mm zone (200) and in the 200–
300 mm zone (300) before and after mitomycin C therapy. LVD before
mitomycin C therapy is marked as a ring, and LVD after mitomycin C
therapy is marked as an asterisk. Sections of four patients were
analysed, in one patient there was no surrounding conjunctiva
represented on the specimen, and only the tumour area was analysed.
Because of the limited number of patients, descriptive analyses were
performed.
Figure 5 Analysis of lymphatic vessels (LVs) in relation to tumour
location. Descriptive scatter plot: in four of seven patients with non-
limbal malignant melanomas (MMs) with involvement of the fornix or
tarsus, the LV density (LVD) was higher than in all limbal/epibulbar
tumour specimens (n=7). Seven patients had limbal/epibulbar MMs,
seven patients had an MM at the fornix or tarsus, and six patients had a
disseminated MM. The analyses of LV parameters (LV number (LVN),
area covered by LV and LVD) did not show any statistically significant
results in these small sample sizes.
Clinical science
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conjunctival MM in the future.
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